SK Biopharmaceuticals Co Ltd
KRX:326030
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
75 700
125 900
|
Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SK Biopharmaceuticals Co Ltd stock under the Base Case scenario is 42 477.81 KRW. Compared to the current market price of 104 700 KRW, SK Biopharmaceuticals Co Ltd is Overvalued by 59%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
SK Biopharmaceuticals Co Ltd
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
Valuation History
Historical valuation for SK Biopharmaceuticals Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
SK Biopharmaceuticals Co Ltd
Balance Sheet Decomposition
SK Biopharmaceuticals Co Ltd
Current Assets | 551.5B |
Cash & Short-Term Investments | 267.5B |
Receivables | 141.7B |
Other Current Assets | 142.3B |
Non-Current Assets | 223.5B |
Long-Term Investments | 85.8B |
PP&E | 41B |
Intangibles | 34B |
Other Non-Current Assets | 62.7B |
Current Liabilities | 338.5B |
Accounts Payable | 3.8B |
Accrued Liabilities | 63.2B |
Short-Term Debt | 50B |
Other Current Liabilities | 221.5B |
Non-Current Liabilities | 98.6B |
Long-Term Debt | 24.4B |
Other Non-Current Liabilities | 74.2B |
Earnings Waterfall
SK Biopharmaceuticals Co Ltd
Revenue
|
511.3B
KRW
|
Cost of Revenue
|
-51.2B
KRW
|
Gross Profit
|
460.1B
KRW
|
Operating Expenses
|
-392.8B
KRW
|
Operating Income
|
67.3B
KRW
|
Other Expenses
|
-9.9B
KRW
|
Net Income
|
57.4B
KRW
|
Free Cash Flow Analysis
SK Biopharmaceuticals Co Ltd
KRW | |
Free Cash Flow | KRW |
Profitability Score
Profitability Due Diligence
SK Biopharmaceuticals Co Ltd's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
SK Biopharmaceuticals Co Ltd's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
SK Biopharmaceuticals Co Ltd's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
SK Biopharmaceuticals Co Ltd's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
SK Biopharmaceuticals Co Ltd
According to Wall Street analysts, the average 1-year price target for SK Biopharmaceuticals Co Ltd is 127 946.25 KRW with a low forecast of 57 570 KRW and a high forecast of 157 500 KRW.
Dividends
Current shareholder yield for SK Biopharmaceuticals Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one SK Biopharmaceuticals Co Ltd stock under the Base Case scenario is 42 477.81 KRW.
Compared to the current market price of 104 700 KRW, SK Biopharmaceuticals Co Ltd is Overvalued by 59%.